Key result
Pulse wave velocity assessment identifies subclinical arterial stiffness and cardiovascular risk in metabolic syndrome.
Why the study?
To review the literature on the relationship between metabolic syndrome and its components and arterial stiffness assessed by PWV, including its clinical usefulness.
Does arterial stiffness assessment by pulse wave velocity provide clinically useful information in patients with metabolic syndrome and its components?
Does arterial stiffness assessment by pulse wave velocity provide clinically useful information in patients with metabolic syndrome and its components?
Assessment of arterial stiffness using pulse wave velocity can help identify subclinical cardiovascular risk in patients with metabolic syndrome, potentially guiding early preventive strategies.
Supports pulse wave velocity for risk stratification in metabolic syndrome; extends associations but leaves randomized outcome trials open.
Metabolic syndrome (MS) is not a single disease but a cluster of metabolic disorders associated with increased risk for development of diabetes mellitus and its complications. Currently, the definition of MS published in 2009 is widely used, but there are more versions of the diagnostic criteria, making it difficult to conduct scientific discourse in this area. Increased arterial stiffness (AS) can predict the development of cardiovascular disease both in the general population and in patients with MS. Pulse wave velocity (PWV), as a standard method to assess AS, may point out subclinical organ damage in patients with hypertension. The decrease in PWV level during antihypertensive therapy can identify a group of patients with better outcomes independently of their reduction in blood pressure. The adverse effect of metabolic disturbances on arterial function can be offset by an adequate program of exercises, which includes mainly aerobic physical training. Non-insulin-based insulin resistance index can predict AS due to a strong positive correlation with PWV. The purpose of this paper is to present the results of the review of the literature concerning the relationship between MS and its components, and AS assessed by PWV, including clinical usefulness of PWV measurement in patients with MS and its components.
No takes yet. Share an insight, caveat, or question.
Starzak et al. (2022) conducted a review in Metabolic Syndrome and Arterial Stiffness. Pulse wave velocity (PWV) assessment was evaluated. Pulse wave velocity assessment is a valuable clinical tool that identifies subclinical arterial stiffness and cardiovascular risk in patients with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: